Loading
A phase 3 trial of Dexamethasone, Palonosetron and Netupitant and palonosetron in Breast cancer, run by University of Rochester NCORP Research Base, completed.
Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer is a phase 3 interventional study registered as NCT03367572 by University of Rochester NCORP Research Base, with 1363 participants recorded, started 2018-04-19 and reaching its primary completion in 2024-04-13. Interventions recorded: Dexamethasone, Laboratory Biomarker Analysis, Netupitant/Palonosetron Hydrochloride, Olanzapine, Placebo, Prochlorperazine, Quality-of-Life Assessment. Conditions recorded: Breast Carcinoma.
Linked to the drug Netupitant and palonosetron because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Netupitant and palonosetron, Breast cancer (all types) and the tag pipeline.
Shares Netupitant and palonosetron, Dexamethasone and the tag pipeline.
Shares Palonosetron and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/